Your browser doesn't support javascript.
loading
Decreased salivary lactoferrin levels are specific to Alzheimer's disease.
González-Sánchez, Marta; Bartolome, Fernando; Antequera, Desiree; Puertas-Martín, Veronica; González, Pilar; Gómez-Grande, Adolfo; Llamas-Velasco, Sara; Herrero-San Martín, Alejandro; Pérez-Martínez, David; Villarejo-Galende, Alberto; Atienza, Mercedes; Palomar-Bonet, Miriam; Cantero, Jose Luis; Perry, George; Orive, Gorka; Ibañez, Borja; Bueno, Hector; Fuster, Valentin; Carro, Eva.
Affiliation
  • González-Sánchez M; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; Neurology Service Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Bartolome F; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain. Electronic address: fbartolome.imas12@h12o.es.
  • Antequera D; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain.
  • Puertas-Martín V; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; CIBER de Enfermedades Cardiovasculares, Madrid, Spain; Hospital Universitario 12 de Octubre Research Institute (imas12), Madrid, Spain.
  • González P; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; CIBER de Enfermedades Cardiovasculares, Madrid, Spain; Hospital Universitario 12 de Octubre Research Institute (imas12), Madrid, Spain.
  • Gómez-Grande A; Nuclear Medicine Service, Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain.
  • Llamas-Velasco S; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; Neurology Service Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Herrero-San Martín A; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; Neurology Service Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Pérez-Martínez D; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; Neurology Service Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Villarejo-Galende A; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; Neurology Service Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Atienza M; Laboratory of Functional Neuroscience, Pablo de Olavide University, Seville, Spain, CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Spain.
  • Palomar-Bonet M; Laboratory of Functional Neuroscience, Pablo de Olavide University, Seville, Spain, CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Spain.
  • Cantero JL; Laboratory of Functional Neuroscience, Pablo de Olavide University, Seville, Spain, CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Spain.
  • Perry G; Department of Biology and Neurosciences Institute, University of Texas at San Antonio, San Antonio, TX, USA.
  • Orive G; Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria, Spain; Networked Center for Biomedical Research in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain.
  • Ibañez B; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain, CIBER de Enfermedades Cardiovasculares, Madrid, Spain; IIS-Fundacion Jiménez Díaz Hospital, Madrid, Spain.
  • Bueno H; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain, CIBER de Enfermedades Cardiovasculares, Madrid, Spain; Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain; Hospital Universitario 12 de Octubre Research Institute (imas12), Cardiology Department
  • Fuster V; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; Icahn School of Medicine at Mount Sinai, New York, New York, United States.
  • Carro E; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain. Electronic address: carroeva@h12o.es.
EBioMedicine ; 57: 102834, 2020 Jul.
Article in En | MEDLINE | ID: mdl-32586758
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Salivary Glands / Alzheimer Disease / Cognitive Dysfunction / Lactoferrin Type of study: Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: EBioMedicine Year: 2020 Document type: Article Affiliation country: España Country of publication: Países Bajos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Salivary Glands / Alzheimer Disease / Cognitive Dysfunction / Lactoferrin Type of study: Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: EBioMedicine Year: 2020 Document type: Article Affiliation country: España Country of publication: Países Bajos